# Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Myeloid Cancer

> **NCT00014495** · PHASE1,PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 32 (actual)

## Conditions studied

- Leukemia
- Myelodysplastic Syndromes
- Myelodysplastic/Myeloproliferative Neoplasms

## Interventions

- **BIOLOGICAL:** filgrastim
- **DRUG:** cytarabine
- **RADIATION:** bismuth Bi213 monoclonal antibody M195

## Key facts

- **NCT ID:** NCT00014495
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-11
- **Primary completion:** 2009-12
- **Final completion:** 2009-12
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2016-01-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00014495

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00014495, "Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Myeloid Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00014495. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*